Computational analyses suggest a potential relationship between KIFC1-associated malignant states and tumor microenvironmental signaling, supporting its value as a prognostic biomarker and potential therapeutic target.
These findings identify LMX1B as a promising prognostic biomarker and provide multiple druggable nodes for precision therapeutic intervention in renal malignancy.
This study identified UBE2C+ proliferative tumor cells as a functionally relevant malignant subpopulation in SCLC and links this state to immune-stromal communication networks within the tumor microenvironment and provides a systems-level framework for investigating the cancer-immunity regulome in SCLC.
Hong-Ling Jia, Yongxuan An, Bing Chen et al.· Frontiers in Immunology· 0 citations
Integrative single-cell RNA sequencing analysis of publicly available datasets from non-small cell lung cancer and breast cancer is performed to systematically map transcriptional heterogeneity and regulatory networks within the TME, providing a systems-level framework of TME organization.
M. O. Odubote, Chiemeka Elochi Emeribe· bioRxiv· 0 citations
These findings identify CDC20 as a recurrence-associated molecular node involved in BaP-responsive malignant biological phenotypes and provide a phenotype-anchored framework linking recurrence biology with environmental exposure-related tumor behavior.
Xu-Chao Dai, Wei Gu, Bo Yu et al.· Frontiers in Cell and Develo...· 0 citations
A mesenchymal gene-expression program linked to inflammation and tissue remodeling was consistently associated with higher tumor grade and shorter survival, and within tumor tissue it was clearly organized in space.
Kesavi HimaBindhu Vuyyuru, Vyshnavi Daggubati, A. P. Karlapudi et al.· Biology· 0 citations
This study provides the first mechanistic characterization of KIF18A dependency in SCLC, identifying SAC competency as the primary determinant of response and establishes a biologically informed framework for patient stratification and rational combination strategies relevant to ongoing KIF18A inhibitor clinical trials...